Human medicine: injectable hydrochloric acid refentanine was evaluated by generic drug consistency

Recently, Yichang Renfu Pharmaceutical Co., Ltd., a subsidiary of Renfu Pharmaceuticals, received the State Drug Administration's "Notice of Approval of Drug Supplemental Applications for Injection hydrochloric acid" (notice number: 2020B05479, 2020B05480, 2020B05481), the drug through generic quality and efficacy consistency evaluation (hereinafter referred to as "consistency evaluation").
hydrochloric acid lyfentane for all-hemp induction and all-hemp to maintain analgesia.
Yichang People's Fund submitted a consistent evaluation application to the State Drug Administration in 2019 and was accepted, with a cumulative research and development investment of about 7 million yuan.
, according to the website of the State Drug Administration, a total of three enterprises in China hold approval for the production of refentanine for injection hydrochloride.
According to Milnet statistics, 2019 hydrochloric acid refentanil injections in China's cities, county levels and townships three terminal public hospital sales of about 1.8 billion yuan, the main manufacturers include Yichang Renfu, Jiangsu Enhua Pharmaceutical Co., Ltd., China Pharmaceutical Group Industry Co., Ltd.
。